Gyre Therapeutics (GYRE) FCF Payout Ratio (2023)
Gyre Therapeutics (GYRE) posted quarterly FCF Payout Ratio of 0.27 for Q3 2023, down 84.29% quarter-over-quarter from 1.7 in Q2 2023.
Powered by 
Analysis
Gyre Therapeutics (GYRE) FCF Payout Ratio (2023) Analysis & Trends
Gyre Therapeutics (GYRE) has reported FCF Payout Ratio for 1 consecutive years, with 0.27 the latest figure, recorded in Q3 2023.
- In Q3 2023, FCF Payout Ratio changed N/A year-over-year to 0.27; the TTM figure through Sep 2023 stood at 0.22 (changed N/A YoY), while the FY2022 annual figure was 7.91, changed N/A from the prior year.
- FCF Payout Ratio slipped to 0.27 in Q3 2023 per GYRE's latest filing, from 1.7 in the prior quarter.
- Across five years, FCF Payout Ratio topped out at 1.7 in Q2 2023 and bottomed at 0.27 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.17 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.07 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 1.70 |
| Mar 31, 2023 | 0.89 |